Repligen (NASDAQ:RGEN) Price Target Cut to $180.00 by Analysts at HC Wainwright

Repligen (NASDAQ:RGEN) had its price target lowered by HC Wainwright from $240.00 to $180.00 in a report issued on Thursday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the stock. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Stock Up 0.6 %

Repligen stock opened at $167.90 on Thursday. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The stock has a market capitalization of $9.41 billion, a PE ratio of -453.77, a price-to-earnings-growth ratio of 4.51 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The business has a 50 day simple moving average of $149.49 and a 200-day simple moving average of $145.57.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. On average, analysts anticipate that Repligen will post 1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Champlain Investment Partners LLC boosted its position in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after buying an additional 850,345 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after acquiring an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. boosted its holdings in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the period. New York State Common Retirement Fund grew its stake in Repligen by 14.4% during the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock worth $84,387,000 after purchasing an additional 71,274 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after purchasing an additional 121,305 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.